Therapeutic | Basiliximab |
Target | IL2RA |
Heavy Chain | QVQLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSS |
Light Chain | QIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIK |
100% seqID Fv Structure | 1mim [Fvs: HL], 3iu3 [Fvs: AB, CD, HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 1mim [Fvs: HL] |
100% seqID Structure | 3iu3 [Fvs: AB, CD, HL] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | NFD |
Recorded Developmental Technology | na |
INN Year Proposed | 1996 |
INN Year Recommended | 1997 |
Companies Involved | Cerimon Pharmaceuticals, Novartis |
Conditions Approved | Renal transplant rejection, Transplant rejection |
Conditions Active | na |
Conditions Discontinued | Ulcerative colitis, Uveitis |
Notes |